MeiraGTx Holdings PLC (MGTX)vsVertex Pharmaceuticals Inc (VRTX)
MGTX
MeiraGTx Holdings PLC
$12.79
-0.47%
HEALTHCARE · Cap: $1.33B
VRTX
Vertex Pharmaceuticals Inc
$515.44
+0.17%
HEALTHCARE · Cap: $130.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 3067% more annual revenue ($12.59B vs $397.50M). VRTX leads profitability with a 35.0% profit margin vs 19.9%. MGTX trades at a lower P/E of 16.0x. VRTX earns a higher WallStSmart Score of 64/100 (C+).
MGTX
Buy61
out of 100
Grade: C+
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MGTX.
Margin of Safety
+46.5%
Fair Value
$963.47
Current Price
$515.44
$448.03 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 76.0%
Revenue surging 8609.0% year-over-year
Attractively priced relative to earnings
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -368.2% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MGTX
The strongest argument for MGTX centers on Operating Margin, Revenue Growth, P/E Ratio. Profitability is solid with margins at 19.9% and operating margin at 76.0%. Revenue growth of 8609.0% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : MGTX
The primary concerns for MGTX are EPS Growth, Market Cap, Return on Equity.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
MGTX profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.
MGTX carries more volatility with a beta of 1.27 — expect wider price swings.
MGTX is growing revenue faster at 8609.0% — sustainability is the question.
VRTX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (64/100 vs 61/100), backed by strong 35.0% margins and 12.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
MeiraGTx Holdings PLC
HEALTHCARE · BIOTECHNOLOGY · USA
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focused on developing treatments for patients living with serious illnesses. The company is headquartered in New York, New York.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?